Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label

    Question

    CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label

    Direct answer

    Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-casgevy-revenue-surges-78-qoq-to-76m-on-pediatric-label-5f23cb

    POLICY
    CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
    Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals.
    CRSPVRTXXBI
    Impact
    72
    SEP 9
    SIG
    88%
    CRSPVRTXXBI
    CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
    Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals.
    → FDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex.
    Impact
    Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals.
    Affected
    CRSPVRTXXBI
    Transmission
    FDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial product revenue inflectionUp1-4wCasgevy revenue expanded 78% quarter-over-quarter to $76 million with pediatric approval.
    VRTXcommercial partnership royalty expansionUp1-4wVertex co-develops and commercializes Casgevy globally with CRISPR Therapeutics.
    XBIclinical-stage biotech sentiment spilloverUp1-5dCRSP commercial progress provides proof-of-concept valuation support for broader gene-editing baskets.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIUpdisagreed159.38 2026-09-09-1.61%-3.26%Pending
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month